What will the Intermune and Abbvie cases mean for the medical devices industry?

I have just written annotations to the Abbvie and Intermune cases under EU pharmaceutical law for the next issue of the Dutch legal journal Jurisprudentie Geneesmiddelenrecht (in Dutch, sorry) but of course that started a train of thought on how these cases might influence the medical devices industry, especially because I have already mentioned that these cases may have an impact on some of the proposed ENVI amendments with respect to transparency of clinical information provided for market access, so her [...] « Read the rest of this article on medicaldeviceslegal »